Insulet Corporation Aktie News

Insulet wird aufgrund starken Wachstums, geringer TAM-Durchdringung und eines wiederkehrenden Umsatzmodells, das langfristiges Aufwärtspotenzial stützt, mit Buy bewertet. PODDs Omnipod-System vereinfacht das Diabetesmanagement durch Automatisierung und Integration, treibt wiederkehrende Pod-Verkäufe voran und reduziert die Belastung für Patienten. Trotz Bedenken wegen GLP-1 zielt PODD auf insul...

Invesco Global Opportunities Fund Class A shares outperformed the MSCI ACWI SMID Index during the first quarter. As of quarter end, the fund was balanced across 176 small- and mid-cap stocks from around the world, with approximately 50% of the fund invested in the US and 48% across non-US. During the quarter, we added and removed several stocks to reflect our desired positioning and upgrade the...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Jonathan (“Jay”) Mazelsky to the Company's Board of Directors, effective July 1, 2026. Mr. Mazelsky joins the Board as an independent director. “We are pleased to welcome Jay to I...

Insulet Corporation has rebounded with strong revenue and profit growth, now approaching the lower end of fair value. PODD delivered Q1 2026 revenue of $761.7M (+33.9% YoY), with net income and operating cash flow nearly doubling. Management forecasts 21–23% revenue growth in 2026, driven by Omnipod 5 adoption and international expansion, despite competitive threats from weight-loss drugs.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort.

ACTON, Mass.--(BUSINESS WIRE)--Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at ADA.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor.

A U.S. ‌appeals court on Thursday overturned a $452 million verdict that ​medical device maker ​Insulet won against Korean rival ⁠EOFlow for allegedly ​stealing trade secrets related ​to its insulin-pump technology.